1 / 31

Rapacuronium: 1. Is a depolarising muscle relaxant. 2. Is typically given in a dose of 1.5 mgs/kg.

Rapacuronium: 1. Is a depolarising muscle relaxant. 2. Is typically given in a dose of 1.5 mgs/kg. 3. Produces intubating conditions within 1 circulation time. 4. Has a duration of effect of 15 - 20 minutes if given in a dose of 1.5 mgs/kg. FTFT.

ashley
Télécharger la présentation

Rapacuronium: 1. Is a depolarising muscle relaxant. 2. Is typically given in a dose of 1.5 mgs/kg.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rapacuronium: • 1. Is a depolarising muscle relaxant. • 2. Is typically given in a dose of 1.5 mgs/kg. • 3. Produces intubating conditions within 1 circulation time. • 4. Has a duration of effect of 15 - 20 minutes if given in a dose of 1.5 mgs/kg.

  2. FTFT

  3. The most likely severe adverse effect of rapacuronium given at a dose of 1.5 mg / kg is: • A. Bradycardia. • B. Myocardial depression. • C. Transient hyperkalaemia. • D. Bronchospasm. • E. Raised intra-ocular pressure.

  4. ANSWER : D • The drug is a low-potency, non-depolarising relaxant and is the 16-N-allyl-17-propionate analogue of vecuronium. It does not increase either serum potassium or intra-ocular pressure

  5. When used within the therapeutic range, which of the following drugs is most likely to potentiate neuromuscular blockade induced by vecuronium? • A. Magnesium. • B. Cyclophosphamide. • C. Lithium. • D. Phenytoin. • E. Bambuterol

  6. ANSWER : A

  7. Which of the following relaxants are likely to be potentiated in a patient on cyclophosphamide? • 1. Suxamethonium. • 2. Cisatracurium. • 3. Mivacurium. • 4. Rapacuronium

  8. TFTF

  9. The constant infusion of Vecuronium for a period of more than 48 hours has been implicated in: • 1. The persistence of residual weakness which may last 3-6 months. • 2. An acute myopathy which becomes apparent as the neuromuscular junction (NMJ) returns to normal. • 3. A cardiomyopathy in asthmatics who have received high dose steroids. • 4. Prolonged NMJ failure in patients with renal failure

  10. ALL CORRECT

  11. Suxamethonium: • 1. Is unlikely to cause muscle pains in a young, ambulant woman. • 2. Causes a rise in serum potassium typically of the order of 0.5-1.0 mmol/L. • 3. Causes an atypically large rise in serum potassium in patients with renal failure. • 4. Causes a rise in serum potassium which is not prevented by pretreatment with a non-depolarizing muscle relaxant

  12. FTFT

  13. Mivacurium: • 1. Is metabolised by plasma cholinesterase. • 2. Has an elimination half-life of about 20 minutes. • 3. Will lower systemic vascular resistance by about 1/3 when given at a dose of 0.2 mg/kg. • 4. Does not cause significant histamine release.

  14. TFTF

  15. Cisatracurium: • 1. Releases histamine when given at a dose of 0.1 mg/kg. • 2. Is metabolised primarily by Hofmann degradation. • 3. Is an aminosteroid compound. • 4. Is metabolised to largely inactive compounds

  16. FTFT

  17. Pancuronium: • 1. Is excreted largely unchanged in the urine. • 2. Has an active metabolite that retains 50% of the activity of pancuronium. • 3. Can cause a myopathy if used for prolonged periods. • 4. Is a benzylquinolinium compound.

  18. TTTF

  19. Which of the following statements are true regarding atracurium: • 1. It theoretically has 16 stereo-isomers. • 2. More than 50% of its neuromuscular blocking activity is due to cisatracurium in the preparation. • 3. It does not need to be given in modified dosage to a patient in renal failure. • 4. It is a benzylisoquinolinium

  20. ALL CORRECT

  21. Histamine release is a feature of administration of which of the following relaxants? • 1. Rocuronium. • 2. Mivacurium. • 3. Vecuronium. • 4. Atracurium.

  22. FTFT

  23. Concomitant use of an anticonvulsant drug such as phenytoin will( SINGLE ANSWER) • A. Potentiate the action of both rocuronium and suxamethonium. • B. Diminish the action of both rocuronium and suxamethonium. • C. Potentiate the action of rocuronium but diminish that of suxamethonium. • D. Potentiate the action of suxamethonium but diminish that of rocuronium. • E. None of the above.

  24. D

  25. Factors which may potentiate the neuromuscular blocking activity of rocuronium include: • 1. Hypermagnesaemia • 2. Hypokalaemia • 3. Respiratory acidosis • 4. Hypothermia

  26. ALL CORRECT

  27. With regard to Cisatracurium and atracurium: • 1. Cisatracurium is the major constituent by weight of atracurium. • 2. Cisatracurium is three times more potent than atracurium. • 3. Cisatracurium has the same onset time as atracurium when given in equipotent dosage. • 4. Cisatracurium has a similar duration of effect to atracurium.

  28. FTFT

  29. Which of the following is NOT metabolised by plasma cholinesterase?A. ProcaineB. CocaineC. DibucaineD. SuxamethoniumE. EsmololF. Mivacurium

  30. In reversing neuromuscular blockade, which of the following combinations is best matched with respect to time of onset?A. Atropine & neostigmineB. Atropine & glycopyrrolateC. Atropine & edrophoniumD. Atropine & physostigmineE. Glycopyrrolate and edrophonium

  31. Rocuronium:A. Monoquaternary at physiological pHB. More lipid soluble than pancuroniumC. 30% metabolised (?deacetylated) in the liverD. Rapid onset is due to its high potencyE. Fastest onset is with 2 times ED95 doseF. Is bisquaternary

More Related